Clinical validation of an autoantibody test for lung cancer

Peter Boyle, C.J. Chapman, S. Holdenrieder, A. Murray, Christopher Robertson, W.C. Wood, P. Maddison, G. Healey, G.H. Fairley, A.C. Barnes, J.F.R. Robertson

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Autoantibodies may be present in a variety of underlying cancers several years before tumours can be detected and testing for their presence may allow earlier diagnosis. We report the clinical validation of an autoantibody panel in newly diagnosed patients with lung cancer (LC).
Three cohorts of patients with newly diagnosed LC were identified: group 1 (n = 145), group 2 (n = 241) and group 3 (n = 269). Patients were individually matched by gender, age and smoking history to a control individual with no history of malignant disease. Serum samples were obtained after diagnosis but before any anticancer treatment. Autoantibody levels were measured against a panel of six tumour-related antigens (p53, NY-ESO-1, CAGE, GBU4-5, Annexin 1 and SOX2). Assay sensitivity was tested in relation to demographic variables and cancer type/stage.
The autoantibody panel demonstrated a sensitivity/specificity of 36%/91%, 39%/89% and 37%/90% in groups 1, 2 and 3, respectively, with good reproducibility. There was no significant difference between different LC stages, indicating that the antigens included covered the different types of LC well.
This assay confirms the value of an autoantibody panel as a diagnostic tool and offers a potential system for monitoring patients at high risk of LC.
Original languageEnglish
Pages (from-to)383-389
Number of pages7
JournalAnnals of Oncology
Volume22
Issue number2
DOIs
Publication statusPublished - 2010

Keywords

  • autoantibodies
  • diagnosed patient
  • clinical validation
  • lung cancer

Cite this